1. The german Healthcare market
Florence, 14th March 2012
© Camera di Commercio Italiana per la Germania

2. The german Healthcare market
Biomedical market
Pharmaceutical market
Biotechnological market
© Camera di Commercio Italiana per la Germania

3. The german Healthcare market
There are 14 main german
“bioregions” which provide a
platform for industrial
development, facilitating the
organic interaction of corporate
and institutional resources in the
16 German Federal States and
abroad
© Camera di Commercio Italiana per la Germania

4. The german Healthcare market
The german biomedical Market
Europe’s leading business location for medical technology and 3rd biggest medical
technology producer and medical services provider in the world -> medium-sized enterprise
sector, strong exporters, and market leaders
200 billion € per year -> increasing all the time
Europe’s strongest location for innovation in this industry
Total turnover of this sector ≈ 18.3 billion €
87,000 employees
7% growth rate per year
© Camera di Commercio Italiana per la Germania

5. The german Healthcare market
The german biotechnological market
 German biotechnology has actually grown during the crisis.
 Number of employees exceeded the 30,000 mark
– Number of employees in dedicated biotechnology companies =>14950
– Number of employees in the other biotechnology-active companies =>16650
 R&D expenditure of dedicated biotech. Companies =>1.05 billion €
 Number of dedicated biotechnology companies =>531
 Number of the other biotechnology-active companies (e. g. pharma, chemicals or seeds
manufacturers) => 114
 In terms of turnover, total revenues stood at 2 billion €
 ≈1 billion € research spending per year
© Camera di Commercio Italiana per la Germania

6. The german Healthcare market
Pharmaceutical - Market
 ≈300 companies
 Workforce of 126,000 people
 Total turnover of 41.5 billion €
 In sales terms, world’s third largest pharmaceutical market ->Net sales are about
22.5 billion € per year
 Drugs production with a market value of ≈27.1 billion € per year
 Europe’s largest biopharmaceuticals producer
 Biopharmaceutical sales account for 16% of the whole German pharmaceutical
market. Since 2000, this level has doubled (10 years)
 Share of the global market remains at around 5% percent
 Around 5 billion € are invested in R&D per year
 Export ratio of around 56%
© Camera di Commercio Italiana per la Germania

7. Clusters
© Camera di Commercio Italiana per la Germania

8. Clusters
© Camera di Commercio Italiana per la Germania

9. Clusters
© Camera di Commercio Italiana per la Germania

10. Clusters
© Camera di Commercio Italiana per la Germania

11. Conclusions
 Companies will continue to look to innovation to drive their strategy and future
success.
 Companies that can sustain their focus on innovation will be the eventual “winners”
in the marketplace.
 The growing complexity of biotechnological research means that it is frequently
necessary to pool expertise from different research disciplines in different
countries
 Only with innovative new technologies and products, driven by robust research
and development inland and in cooperation with partners abroad, can a full
growth be achieved and sustained.
-> let European countries cooperate with each other!
© Camera di Commercio Italiana per la Germania